Researchers reveal the risks of laryngeal edema after chimeric antigen receptor T-cell therapy for relapsed or refractory B-cell lymphomas Chimeric antigen receptor (CAR) T-cell therapy is a type of ...

THE early clinical descriptions of lupus erythematosus by Biett 1 in 1838 and Hebra 2 in 1845 characterized the disease solely as a dermatologie entity. However, in 1872 Kaposi 3 stressed the systemic ...

ACUTE circumscribed subepithelial edema of the skin was recognized as a distinct clinical entity by Milton 1 and by Quincke, 2 and shortly thereafter was termed angioneurotic edema by Strübing. 3 In ...

Laryngeal edema is a severe adverse effect of CAR T-cell therapy in patients with refractory or relapsed B-cell lymphomas You are free to share and adapt the infographic material but attribution is ...

There are 2 main ways in which patients may experience dyspnea originating in the larynx. First, there may be structural interference with air flow due to an anatomic abnormality. In other words, ...

A term baby boy presented to our institution with stridor and cyanosis. He was born at 40 weeks gestation at the referring hospital to a 23-year-old primigravida woman by vacuum-assisted vaginal ...

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize ...

Laryngeal hypersensitivity may be a key factor in refractory and unexplained cough. Defining the characteristics and better understanding laryngeal hypersensitivity may help in the treatment of ...

Patients with chronic symptoms are evaluated by ENT physicians and, after exclusion of malignancy by laryngoscopy, they are often diagnosed with GERD based on the presence of chronic irritation in the ...

The article “Prognostic Accuracy of Computed Tomography Signs for Laryngeal Cancer Patients Undergoing Laryngectomy” by Beitler et al 6 offers a careful retrospective clinicopathologic analysis of the ...

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize ...